OasisLMS

Recorded Date: February 1, 2025

Expiration Date: January 30, 2028

This recorded concurrent session from the 2025 NANS Annual Meeting explores the evolving role of peripheral nerve stimulation (PNS) in comparison to neuraxial neuromodulation therapies, including spinal cord stimulation (SCS) and dorsal root ganglion stimulation (DRGS). Using a dynamic PRO/CON debate format, expert faculty examine the appropriateness of these therapies in the treatment of complex regional pain syndrome (CRPS), non-surgical refractory low back pain, and focal distribution neuropathic pain.

In addition to expert-led discussions, the session features oral abstract presentations highlighting emerging clinical and translational research in peripheral nerve stimulation. Through this activity, learners will gain a deeper understanding of the indications, limitations, and clinical decision-making considerations surrounding PNS, SCS, and DRGS, while exploring evolving evidence and future directions in neuromodulation therapy.

To access the NANS eLearning Center and register for this content, log in using your NANS account username and password.

• Have a NANS account? Click Login.
• Need an account? Click Create Account and complete the form.
• Questions about your NANS account? Email membership@neuromodulation.org or call (773) 648-7845 (Mon–Fri, 8:30 AM–5:00 PM CT).

Following participation in this activity, learners will be able to:

• Identify indications for and limitations with PNS utilization.
• Compare PNS to SCS and DRGS in context of complex regional pain syndrome,  Non-Surgical Refractory Low Back Pain, and  focal distribution neuropathic pain.
• Better determine appropriateness of differing neuromodulation therapies for treatment of these painful conditions.

Welcome
Jay Karri, MD, MPH and Nasir Hussain, MD, MSc

Treating Complex Regional Pain Syndrome- Pro: Favor PNS as a treatment modality
Saba Javed, MD

Treating Complex Regional Pain Syndrome- Con: Favor DRGS as a treatment modality
David Dickerson, MD

Treating Non-Surgical Refractory Low Back Pain- Pro: Favor PNS (including restorative neurostimulation) as a treatment modality
Christopher Gilligan, MD
    
Treating Non-Surgical Refractory Low Back Pain- Con: Favor SCS as a treatment modality
Nasir Hussain MD, MSc

Treating Focal Distribution Neuropathic Pain- Pro: Favor PNS as a treatment modality
Jay Karri, MD, MPH

Treating Focal Distribution Neuropathic Pain- Con: Favor SCS/DRGS as a treatment modality
Matthew Chung, MD

Oral Abstract Presentation: Pain Outcomes from the COMFORT 2 Randomized Control Trial for Peripheral Nerve Stimulation- Early Results
John Hatheway, MD

Oral Abstract Presentation: Real World Data Shows Long-Term Pain Relief with Peripheral Nerve Stimulation Delivered from Micro-IPG
John Hatheway, MD

Oral Abstract Presentation: Anti-inflammatory mechanism and central pathway of auricular vagal nerve stimulation on visceral hyperalgesia in rats
Kaijie Wang

Closing Discussion
Jay Karri, MD, MPH and Nasir Hussain, MD, Msc

Any faculty member not on the disclosure list has reported nothing to disclose.
 
Matthew Chung, MD | Speaker
Saluda Medical: Consulting Fees (Ongoing)

David Dickerson, MD | Speaker
Abbott/St. Jude Medical: Consulting Fees (Ongoing)|Abbott/St. Jude Medical: Contracted Research (Ongoing)|Abbott/St. Jude Medical: Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers' bureaus) (Ongoing)|Abbott/St. Jude Medical: Speakers' Bureau (Ongoing)|Biotronik: Contracted Research (Ongoing)|Biotronik: Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers' bureaus) (Ongoing)|Biotronik: Speakers' Bureau (Ongoing)|SPR therapeutics: Consulting Fees (Ongoing)|SPR therapeutics: Contracted Research (Ongoing)|SPR therapeutics: Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers' bureaus) (Ongoing)|SPR therapeutics: Speakers' Bureau (Ongoing)|Vertex: Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers' bureaus) (Ongoing)|Vertos: Consulting Fees (Ongoing)|Vertos: Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers' bureaus) (Ongoing)|Vertos: Speakers' Bureau (Ongoing)

Christopher Gilligan, MD | Speaker
Biotronik: Consulting Fees (Ongoing)|Iliad Lifesciences: Consulting Fees (Ongoing)|Mainstay Medical: Consulting Fees (Ongoing)|Mainstay Medical: Stock Options (Ongoing)|Persica: Consulting Fees (Ongoing)|Saluda Medical: Consulting Fees (Ongoing)

John Hatheway, MD | Oral Abstract Presenter
Medtronic: Consulting Fees (Ongoing)|Medtronic: Contracted Research (Ongoing)|Medtronic: Fees for Non-CME/CE Services (e.g., advisor) (Ongoing)|Medtronic: Speakers' Bureau (Ongoing)|Nalu Medical: Consulting Fees (Ongoing)|Nalu Medical: Contracted Research (Ongoing)|Nalu Medical: Fees for Non-CME/CE Services (e.g., advisor) (Ongoing)|Nalu Medical: Speakers' Bureau (Ongoing)|SI Bone: Contracted Research (Ongoing)